Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 3/2012

01-06-2012 | CARDIOVASCULAR RISK AND HYPERTENSION (PW de LEEUW AND AH GRADMAN, SECTION EDITORS)

Vitamin D and Cardiovascular Risk

Authors: Shweta R. Motiwala, Thomas J. Wang

Published in: Current Hypertension Reports | Issue 3/2012

Login to get access

Abstract

Vitamin D deficiency is a common condition that has well-documented effects on musculoskeletal health. A growing body of literature has related vitamin D deficiency to other chronic disorders, including cardiovascular disease. Several plausible biological mechanisms have been postulated to explain this association, including the effect of poor vitamin D status on intermediate risk factors (eg, hypertension and diabetes), neurohormonal activation, inflammation, and cardiac remodeling. These mechanisms have been explored in experimental and animal studies, as well as several small interventional studies. The results of the controlled trials have not been conclusive to date. In this review, we summarize the existing studies investigating the effects of vitamin D on cardiovascular health, and propose that additional well-designed, prospective, randomized controlled trials are necessary to delineate the appropriate role of vitamin D supplementation in reducing the burden of cardiovascular disease.
Literature
1.
2.
Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev. 1995;16:200–57.PubMed
3.
Stumpf WE, Sar M, Reid FA, et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979;206:1188–90.PubMedCrossRef
4.
Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28.PubMed
5.
•• Institute of Medicine. Dietary references intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2010. These guidelines from the IOM provide recommendations regarding minimum daily intake of both calcium and vitamin D.
6.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.PubMedCrossRef
7.
Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002;30:771–7.PubMedCrossRef
8.
• Ginde AA, Liu MC, Camargo CA. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern Med. 2009;169:626–32. This large study of epidemiologic trends of vitamin D insufficiency suggests that its prevalence is increasing and that there are important racial and ethnic disparities that have persisted over time. PubMedCrossRef
9.
10.
Merke J, Hofmann W, Goldschmidt D, Ritz E. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int. 1987;41:112–4.PubMedCrossRef
11.
Somjen D, Weisman Y, Kohen F, et al. 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;111:1666–71.PubMedCrossRef
12.
Merke J, Milde P, Lewicka A, et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3: studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest. 1989;83:1903–15.PubMedCrossRef
13.
Zanello SB, Collins ED, Marinissen MJ, et al. Vitamin D receptor expression in chicken muscle tissue and cultured myoblasts. Horm Metab Res. 1997;29:231–6.PubMedCrossRef
14.
O’Connell TD, Giacherio DA, Jarvis AK, Simpson RU. Inhibition of cardiac myocyte maturation by 1,25-dihydroxyvitamin D3. Endocrinology. 1995;136:482–8.PubMedCrossRef
15.
O’Connell TD, Berry JE, Jarvis AK, et al. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol. 1997;272:H1751–8.PubMed
16.
Oh J, Weng S, Felton SK, et al. 1,25(OH)2 Vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009;120:687–98.PubMedCrossRef
17.
Li YC, Kong J, Wei M, et al. 1,25-dihydroxyvitamin (D)3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229–38.PubMed
18.
Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007;20:713–9.PubMedCrossRef
19.
Scragg RK, Camargo Jr CA, Simpson R. Relation of serum 25-hydroxyvitamin D to heart rate and cardiac work (from the National Health and Nutrition Examination Surveys). Am J Cardiol. 2010;105:122–8.PubMedCrossRef
20.
Sabanavagam C, Shankar A, Somasundaram S. Serum vitamin D level and prehypertension among subjects free of hypertension. Kidney Blood Press Res. 2011;35:106–13.CrossRef
21.
Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063–9.PubMedCrossRef
22.
Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52:828–32.PubMedCrossRef
23.
Wang L, Manson JE, Buring JE, et al. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension. 2008;51:1073–9.PubMedCrossRef
24.
Margolis KL, Martin LW, Ray RM, et al. A prospective study of serum 25-hydroxyvitamin D levels, blood pressure, and incident hypertension in postmenopausal women. Am J Epidemiol. 2012;175:22–32.PubMedCrossRef
25.
Jorde R, Figenschau Y, Emaus N, et al. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension. 2010;55:792–8.PubMedCrossRef
26.
Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens. 2011;29:636–45.PubMedCrossRef
27.
Zhang Y, Kong J, Deb DK, et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol. 2010;21:966–73.PubMedCrossRef
28.
Zhou C, Lu F, Cao K, et al. Calcium-independent and 1,2(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout nice. Kidney Int. 2008;74:170–9.PubMedCrossRef
29.
Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007;282:29821–30.PubMedCrossRef
30.
Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension: relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105:649–54.PubMed
31.
• Vaidya A, Forman JP, Hopkins PN, et al. 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst. 2011;12:311–19. This is a cross-sectional analysis of hypertensive participants that confirms associations between vitamin D level, PRA, and salt sensitivity of blood pressure. It provides additional support for the proposed influence of vitamin D on the RAS. PubMedCrossRef
32.
Vaidya A, Forman J. Vitamin D and hypertension: current evidence and future directions. Hypertension. 2010;56:774–9.PubMedCrossRef
33.
Margolis KL, Ray RM, Van Horn L, et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women’s Health Initiative Randomized Trial. Hypertension. 2008;52:847–55.PubMedCrossRef
34.
Jorde R, Sneve M, Torjesen PA, et al. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med. 2010;267:462–72.PubMedCrossRef
35.
Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr. 1995;49:640–6.PubMed
36.
Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86:1633–7.PubMedCrossRef
37.
Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009;27:1948–54.PubMedCrossRef
38.
• Pittas AG, Chung M, Trikalinos T, et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152:307–14. This meta-analysis includes observational and interventional studies investigating multiple cardiometabolic end points in response to vitamin D supplementation and UVB radiation. The trials showed no clinically significant effect of vitamin D supplementation at the doses studied, and the authors suggest that further well-designed randomized, prospective trials are necessary. PubMed
39.
Wu SH, Ho SC, Zhong L. Effects of vitamin D supplementation on blood pressure. South Med J. 2010;103:729–37.PubMedCrossRef
40.
• Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:1931–42. This is a recent meta-analysis of a large number of intervention trials; it found no significant reduction in overall cardiovascular risk or mortality, or blood pressure, associated with vitamin D supplementation. The authors note significant heterogeneity of study design and analysis and rate the quality of available evidence as low to moderate. PubMedCrossRef
41.
Littorin B, Blow P, Scholin A, et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia. 2006;49:2847–52.PubMedCrossRef
42.
Janner M, Ballinari P, Mullis PE, Fluck CE. High prevalence of vitamin D deficiency in children and adolescents with type 1 diabetes. Swiss Med Wkly. 2010;140:w13091.PubMed
43.
Vitamin D. supplement in early childhood and risk for Type 1 (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia. 1999;42:51–4.CrossRef
44.
Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358:1500–3.PubMedCrossRef
45.
Stene LC, Joner G, for the Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case–control study. Am J Clin Nutr. 2003;78:1128–34.PubMed
46.
Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child. 2008;93:512–7.PubMedCrossRef
47.
Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr. 2004;79:820–5.PubMed
48.
Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care. 2010;33:1379–81.PubMedCrossRef
49.
Hirani V. Relationship between vitamin D and hyperglycemia in older people from a nationally representative population survey. J Am Geriatr Soc. 2011;59:1786–92.PubMedCrossRef
50.
Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27:2813–8.PubMedCrossRef
51.
Brock KE, Huang WY, Fraser DR, et al. Diabetes prevalence is associated with serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in US middle-aged Caucasian men and women: a cross-sectional analysis within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Br J Nutr. 2011;106:339–44.PubMedCrossRef
52.
Pittas AG, Sun Q, Manson JE, et al. Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care. 2010;33:2021–3.PubMedCrossRef
53.
Pittas A, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006;29:650–6.PubMedCrossRef
54.
Kayaniyil S, Retnakaran R, Harris SB, et al. Prospective associations of vitamin D with beta-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes. 2011;60:2947–53.PubMedCrossRef
55.
Gagnon C, Lu ZX, Magliano DJ, et al. Serum 25-dihydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Diabetes Care. 2011;34:1133–8.PubMedCrossRef
56.
Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209:823–5.PubMedCrossRef
57.
Resnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care. 1991;14:505–20.PubMedCrossRef
58.
Maestro B, Molero S, Bajo S, et al. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct. 2002;20:227–32.PubMedCrossRef
59.
Gysemans CA, Cardozo AK, Callewaert H, et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in non-obese diabetic mice. Endocrinology. 2005;146:1956–64.PubMedCrossRef
60.
Leung PS, Chappell MC. A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int J Biochem Cell Biol. 2003;35:838–46.PubMedCrossRef
61.
Leung KK, Leung PS. Effects of hyperglycemia on angiotensin II receptor type 1 expression and insulin secretion in an INS-1E pancreatic beta-cell line. JOP. 2008;9:290–9.PubMed
62.
Cole BK, Keller SR, Wu R, et al. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension. 2010;55:715–21.PubMedCrossRef
63.
Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 2006;55:367–74.PubMedCrossRef
64.
Cheng Q, Li YC, Boucher BJ, Leung PS. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia 2011;54:2077–81.PubMedCrossRef
65.
Zeitz U, Weber K, Soegiarto D, et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003;17:509–11.PubMed
66.
Gysemans C, van Etten E, Overbergh L, et al. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes. 2008;57:269–75.PubMedCrossRef
67.
Bland R, Markovic D, Hills CE, et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89–90:121–5.PubMedCrossRef
68.
Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol. 1999;160:87–95.PubMedCrossRef
69.
Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endoc J. 2000;47:383–91.CrossRef
70.
Calle C, Maestro B, Garcia-Arencibia M. Genomic actions of 1,25-dihydroxyvitamin D3 on insulin receptor gene expression, insulin receptor number and insulin activity in the kidney, liver and adipose tissue of streptozotocin-induced diabetic rats. BMC Mol Biol. 2008;9:65.PubMedCrossRef
71.
Mathieu C, Waer M, Laureys J, et al. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia. 1994;37:552–8.PubMedCrossRef
72.
Mathieu C, Laureys J, Sobis H, et al. 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes. 1992;41:1491–5.PubMedCrossRef
73.
Gregori S, Giarratana N, Smiroldo S, et al. 1alpha,25-dihydroxyvitamin D3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes. 2002;51:1367–74.PubMedCrossRef
74.
Pitocco D, Crino A, Di Stasio E, et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med. 2006;23:920–3.PubMedCrossRef
75.
Li X, Liao L, Yan X, et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev. 2009;25:411–6.PubMedCrossRef
76.
Walter M, Kaupper T, Adler K, et al. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirements in adults with new-onset type 1 diabetes. Diabetes Care. 2010;33:1443–8.PubMedCrossRef
77.
Bizzarri C, Pitocco D, Napoli N, et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care. 2010;33:1962–3.PubMedCrossRef
78.
Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011;94:486–94.PubMedCrossRef
79.
Borissova AM, Tankova T, Kirilov G, et al. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract. 2003;57:258–61.PubMed
80.
Nazarian S, St Peter JV, Boston RC, et al. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res. 2011;158:276–81.PubMedCrossRef
81.
von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient – a randomised, placebo-controlled trial. Br J Nutr. 2009;103:549–55.CrossRef
82.
Parekh D, Sarathi V, Shivane VK, et al. Pilot study to evaluate the effect of short-term improvement in vitamin D status on glucose tolerance in patients with type 2 diabetes mellitus. Endocr Pract. 2010;16:600–8.PubMedCrossRef
83.
Witham MD, Dove FJ, Dryburgh M, et al. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2010;53:2112–9.PubMedCrossRef
84.
Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30:980–6.PubMedCrossRef
85.
de Boer IH, Tinker LF, Connelly S, et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women’s Health Initiative. Diabetes Care. 2008;31:701–7.PubMedCrossRef
86.
Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92:2017–29.PubMedCrossRef
87.
Parker J, Hashmi O, Dutton D, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas. 2010;65:225–36.PubMedCrossRef
88.
Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011;65:1005–15.PubMedCrossRef
89.
Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int J Epidemiol. 1981;10:337–41.PubMedCrossRef
90.
91.
Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167:1159–65.PubMedCrossRef
92.
Kendrick J, Targher G, Smits G, Chonchol M. 25-hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009;205:255–60.PubMedCrossRef
93.
Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755–60.PubMed
94.
de Boer IH, Kestenbaum B, Shoben AB, et al. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20:1805–12.PubMedCrossRef
95.
Young KA, Snell-Bergeon JK, Naik RG, et al. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care. 2011;34:454–8.PubMedCrossRef
96.
Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–11.PubMedCrossRef
97.
Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174–80.PubMedCrossRef
98.
• Anderson JL, May HT, Horne BD, et al. for the Intermountain Heart Collaborative (IHC) Study Group. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106:963–8. This was a large observational study that provides further evidence for associations between vitamin D levels and cardiovascular disease. PubMedCrossRef
99.
Ginde AA, Scragg R, Schwartz RS, Camargo Jr CA. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57:1595–603.PubMedCrossRef
100.
• Zhao G, Ford ES, Li C, Croft JB. Serum 25-hydroxyvitamin D levels and all-cause and cardiovascular disease mortality among US adults with hypertension: the NHANES linked mortality study. J Hypertens. 2012;30:284–9. This was a large population-based study linking vitamin D status with both all-cause and cardiovascular-related mortality, noting a strong inverse association between vitamin D level and cardiovascular death. PubMedCrossRef
101.
Dreschler C, Pilz S, Obermayer-Pietsch B, et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J. 2010;31:2253–61.CrossRef
102.
Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340–9.PubMedCrossRef
103.
Pilz S, Marz W, Wellnitz B, et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008;93:3927–35.PubMedCrossRef
104.
Zitterman A, Iodice S, Pilz S, et al. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr. 2012;95:91–100.CrossRef
105.
Kasuga H, Hosogane N, Matsuoka K, et al. Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. Biochem Biophys Res Commun. 2002;297:1332–8.PubMedCrossRef
106.
Shen H, Bielak FL, Ferguson JF, et al. Association of the vitamin D metabolism gene CYP24A1 with coronary artery calcification. Arterioscler Thromb Vasc Biol. 2010;30:2648–54. PubMedCrossRef
107.
Sun Q, Shi L, Rimm EB, et al. Vitamin D intake and risk of cardiovascular disease in US men and women. Am J Clin Nutr. 2011;94:534–42.PubMedCrossRef
108.
Vacek JL, Vanga SR, Good M, et al. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol. 2012;109:359–63.PubMedCrossRef
109.
Manson JE, Allison MA, Carr JJ, et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women’s Health Initiative. Menopause. 2010;17:683–91.PubMed
110.
Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007;115:846–54.PubMedCrossRef
111.
LaCroix A, Kotchen J, Anderson G, et al. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women’s Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2009;64:559–67.PubMedCrossRef
112.
Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167:1730–7.PubMedCrossRef
113.
Van der Schueren BJ, Verstuyf A, Mathieu C. Straight from D-Heart: vitamin D status and cardiovascular disease. Curr Opin Lipidol. 2012;23:17–23.PubMedCrossRef
Metadata
Title
Vitamin D and Cardiovascular Risk
Authors
Shweta R. Motiwala
Thomas J. Wang
Publication date
01-06-2012
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 3/2012
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-012-0262-y

Other articles of this Issue 3/2012

Current Hypertension Reports 3/2012 Go to the issue

SECONDARY HYPERTENSION: ADRENAL AND NERVOUS SYSTEM MECHANISMS (S OPARIL AND KH BERECEK, SECTION EDITORS)

Neurogenic Hypertension and Elevated Vertebrobasilar Arterial Resistance: Is There a Causative Link?

SECONDARY HYPERTENSION: ADRENAL AND NERVOUS SYSTEM MECHANISMS (S OPARIL AND KH BERECEK, SECTION EDITORS)

Adipose Tissue as Regulator of Vascular Tone

CARDIOVASCULAR RISK AND HYPERTENSION (PW DE LEEUW AND AH GRADMAN, SECTION EDITORS)

Nocturnal Blood Pressure, Morning Blood Pressure Surge, and Cerebrovascular Events

CARDIOVASCULAR RISK AND HYPERTENSION (PW de LEEUW and AH GRADMAN, SECTION EDITORS)

Angiotensin Receptor Blockers and Tumorigenesis: Something To Be (or Not To Be) Concerned About?

SECONDARY HYPERTENSION: ADRENAL AND NERVOUS SYSTEM MECHANISMS (S OPARIL AND KH BERECEK, SECTION EDITORS)

Hypertension in Postmenopausal Women

CARDIOVASCULAR RISK AND HYPERTENSION (PW DE LEEUW AND AH GRADMAN, SECTION EDITORS)

Dietary Sodium Intake and Cardiovascular Mortality: Controversy Resolved?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits